Replies to post #779298 on NorthWest Biotherapeutics Inc (NWBO)

[Zadie420]

Gary- I have been preaching for long time that NWBO should have started D vaccine for couple of indications for small samples (N<40) just to be ahead of schedule. But If I remember, NWBO on latest communications said they will use tumor shrinkage as their primary end and expect the time for final analysis to be much shorter. Unfortunately we have not heard anything yet about the start of the trials.

[Chiugray]

Gary, On your point that DCVax-Direct will need adjuvants like Poly-ICLC to cure cancer, I agree to a point, especially for late, stage 4 aggressive cancers where immune suppression is severe.

But could the paradigm shift for a cancer cure come from an early intervention of DCVax, not just the addition of adjuvants? Because DCVax is inherently a vaccine, giving it to a cancer patient earlier, ideally at an earlier stage, provides a higher probability for a durable immune response, ie cure.

What if the reason many cancers progress to stage 4 is because:
- A patient’s initial treatment has limitations
- They do not eliminate all the cancer cells, leaving the residual cells to evolve and grow
- This gives the cancer time to develop resistance and metastasize, turning a local cancer into a later-stage, systemic, and aggressive cancer

The earlier intervention, disruptive potential of DCVax-Direct:
- Earlier diagnosis via liquid biopsies and blood tests
- Direct turnaround time is approx 3 weeks*
- First-line treatment potential
- Early treatment means clinical advantage, before the tumor can put up defenses or mutate too much
- Immune durability and low cost translate to high QALY and health insurers providing improved coverage, which is crucial for market adoption


* DCVax-Direct (no surgery, no lysate): approx 3 weeks
- Diagnosis – day 0
- Leukapheresis – 1 day
- Transport – ~2 days
- DC manufacturing - ~7 days
- Quality control, release testing – ~1 day
- Scheduling first injection – 1 week